Abstract  Description  Claims  Drawing  Search report  Cited references 

US62008851   [0001] 
US5091513A   [0033] 
US5132405A   [0033] 
US4956778A   [0033] 
US20050196754A   [0033]  [0033] 
US8357783B   [0073] 
US7446190B   [0105]  [0105]  [0149]  [0149] 
US20130071414A   [0149] 
WO2014055668A   [0149] 
US5399346A   [0168] 

Dictionary of Microbiology and Molecular Biology   [0026] 
The Cambridge Dictionary of Science and Technology   [0026] 
The Glossary of Genetics   [0026] 
The Harper Collins Dictionary of Biology   [0026] 
J. Nucl. Med.   [0029] 
Proc. Nat. Acad. Sci. USA   [0033] 
Hyrbidoma   [0033] 
J Cachexia Sarcopenia Muscle   [0033] 
J Imunol   [0033] 
Thromb Haemost   [0033] 
J Clin Invst   [0033] 
Immunotechnology   [0033] 
Ther Immunol   [0033] 
J Bioi Chern   [0033] 
Nat Biotech   [0033] 
Crit Rev Immunol   [0033] 
BioChim Biophys Acta   [0033] 
Methods Enzymol.   [0039] 
Methods Enzymol.   [0039] 
Science   [0041] 
Proc. Natl. Acad. Sci., USA   [0041] 
Current Protocols in Molecular Biology   [0041] 
Guide to Molecular Cloning Techniques   [0041] 
Molecular Cloning: A Laboratory Manual   [0041] 
Seventh Training Course on Radioligand Assay Techniques   [0074] 
Mol. Cancer Therapy   [0087] 
Cancer Discovery   [0105] 
Cancer Immunol Res   [0140] 
The Basic Principles of Chimeric Antigen Receptor Design   [0149] 
Nature Medicine   [0149] 
Clin Cancer Res.   [0149] 
Molecular Therapy   [0149] 
Nat Rev Cancer   [0152] 
Science   [0152] 
J Immunol   [0152] 
J Immunol   [0152] 
Cancer Res   [0152] 
Blood   [0152] 
Mol. Cell. Biol.   [0166] 
Mol. Cell. Biol.   [0166] 
Proc. Natl. Acad. Sci. USA   [0166] 
Blood   [0167] 
Exp. Hemat.   [0167] 
J. Clin. Invest.   [0167] 
Human Gene Therapy   [0168] 
Current Eye Research   [0168] 
Journal of Virology   [0168] 
Science   [0168] 
Proc. Natl. Acad. Sci. U.S.A.   [0168] 
Human Gene Therapy   [0168] 
Science   [0168] 
BioTechniques   [0168] 
Current Opinion in Biotechnology   [0168] 
The Lancet   [0168] 
Nucleic Acid Research and Molecular Biology   [0168] 
Science   [0168] 
Blood Cells   [0168] 
Biotechnology   [0168] 
Science   [0168] 
Chest   [0168] 
N. Engl. J. Med   [0168] 
Proc. Nat!. Acad. Sci. U.S.A.   [0180] 
Neuroscience Letters   [0180] 
Am. J. Med. Sci.   [0180] 
Methods in Enzymology   [0180] 
Journal of Biological Chemistry   [0180] 
Journal of Biological Chemistry   [0180] 
Science   [0180] 
Molecular Cloning: A Laboratory Manual   [0183] 
REMINGTON'S PHARMACEUTICAL SCIENCE   [0192] 
Clin Cancer Res   [0227] 
Clin Cancer Res   [0227] 
Molecular Cloning: A Laboratory Manual   [0237] 
Oligonucleotide Synthesis   [0237] 
Animal Cell Culture   [0237] 
Methods in Enzymology   [0237] 
Gene Transfer Vectors for Mammalian Cells   [0237] 
Current Protocols in Molecular Biology   [0237] 
PCR: The Polymerase Chain Reaction   [0237] 
Current Protocols in Immunology   [0237] 
Expression levels by retroviral vectors based upon the N2 and the MFG backbones   [0292] 
Triple-negative breast cancer: disease entity or title of convenience   [0371] 
Basal-like breast cancer: a critical review   [0371] 
Subtypes of breast cancer show preferential site of relapse   [0371] 
Triple-negative breast cancer: clinical features and patterns of recurrence   [0371] 
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer   [0371] 
Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas   [0371] 
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer   [0371] 
Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer   [0371] 
Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer   [0371] 
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias   [0371] 
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia   [0371] 
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1   [0371] 
Adoptive cell transfer: a clinical path to effective cancer immunotherapy   [0371] 
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens   [0371] 
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts   [0371] 
Targeted elimination of prostate cancer by genetically directed human T lymphocytes   [0371] 
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor   [0371] 
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer   [0371] 
The promise and potential pitfalls of chimeric antigen receptors   [0371] 
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy   [0371] 
The basic principles of chimeric antigen receptor design   [0371] 
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes   [0371] 
T cell-encoded CD80 and 4-1BBL induce auto- and transco-stimulation, resulting in potent tumor rejection   [0371] 
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes   [0371] 
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen   [0371] 
Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization   [0371] 
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients   [0371] 
Mesothelin targeted cancer immunotherapy   [0371] 
Malignant mesothelioma 2008   [0371] 
Molecular targets and targeted therapies for malignant mesothelioma   [0371] 
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study   [0371] 
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions   [0371] 
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure   [0371] 
Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3   [0371] 
Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells   [0371] 
A Binding Domain on Mesothelin for CA125/MUC16   [0371] 
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients   [0371]  [0371] 
Mesothelin promotes invasion and metastasis in breast cancer cells   [0371] 
Clinicopathological significance of mesothelin expression in invasive breast cancer   [0371] 
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases   [0371] 
Soluble mesothelin-related protein--a blood test for mesothelioma   [0371] 
ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma   [0371] 
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study   [0371] 
MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus   [0371] 
Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study   [0371] 
Non-invasive diagnosis of pleural malignancies: the role of tumour markers   [0371] 
Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma   [0371] 
Mesothelin is not required for normal mouse development or reproduction   [0371] 
Mesothelin-targeted agents in clinical trials and in preclinical development   [0371] 
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers   [0371] 
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients   [0371] 
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin   [0371] 
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity   [0371] 
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor   [0371] 
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor   [0371] 
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor   [0371] 
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases   [0371] 
Mesothelin, a novel immunotherapy target for triple negative breast cancer   [0371] 
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice   [0371] 
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion   [0371] 
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice   [0371] 
Interleukin-12: biological properties and clinical application   [0371] 
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro   [0371] 
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function   [0371] 
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression   [0371] 
Inhibition of angiogenesis in vivo by interleukin 12   [0371] 
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma   [0371] 
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma   [0371] 
Intratumoral injection of IL-12 plasmid DNAresults of a phase I/IB clinical trial   [0371] 
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study   [0371] 
Antitumor and antimetastatic activity of interleukin 12 against murine tumors   [0371] 
Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy   [0371] 
Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12   [0371] 
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer   [0371] 
Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy   [0371] 
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies   [0371] 
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion   [0371] 
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells   [0371] 
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production   [0371] 
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors   [0371] 
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy   [0371] 
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer   [0371] 
Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice   [0371] 
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer   [0371] 
An in vivo platform for tumor biomarker assessment   [0371] 
Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden   [0371] 
Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery   [0371] 
Virally-directed fluorescent imaging (VFI) can facilitate endoscopic staging   [0371] 
Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus   [0371] 
Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus   [0371] 
Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus   [0371] 
Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses   [0371] 
Inducible apoptosis as a safety switch for adoptive cell therapy   [0371] 
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia   [0371] 
Nivolumab plus ipilimumab in advanced melanoma   [0371] 
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma   [0371] 
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells   [0371] 
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele   [0371] 
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning   [0371] 
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning   [0371] 
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy   [0371] 
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase   [0371] 
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo   [0371] 
A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data   [0371] 
Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients   [0371] 
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer   [0371] 
Management of malignant pleural effusions   [0371] 
Malignant mesothelioma   [0371] 
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma   [0371] 
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection   [0371] 
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients   [0371] 
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma   [0371] 
Translational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma   [0371] 
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation   [0371] 
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia   [0371] 
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia   [0371] 
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells   [0371] 
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma   [0371] 
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma   [0371] 
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy   [0371] 
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression   [0371] 
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains   [0371] 
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions   [0371] 
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy   [0371] 
Systemic effects of local radiotherapy   [0371] 
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy   [0371] 
Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor   [0371] 
Tumor and liver drug uptake following hepatic artery and portal vein infusion   [0371] 
Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan   [0371] 
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer   [0371] 
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer   [0371] 
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis   [0371] 
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas   [0371] 
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)   [0371] 
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma   [0371] 
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies   [0371] 
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity   [0371] 
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines   [0371] 
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs) Oncoimmunology   [0371] 
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers   [0371] 
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans   [0371] 
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells   [0371] 
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma   [0371] 
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells   [0371] 
Novel approaches to enhance the specificity and safety of engineered T cells   [0371] 
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses   [0371] 
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies   [0371] 
Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters   [0371] 
Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor   [0371] 
Regional liver therapy using oncolytic virus to target hepatic colorectal metastases   [0371] 
51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells   [0371]  [0371] 
Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer   [0371] 
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer   [0371] 
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo   [0371] 
Targeting tumours with genetically enhanced T lymphocytes   [0371] 
The basic principles of chimeric antigen receptor design   [0371] 
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia   [0371] 
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias   [0371] 
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia   [0371] 
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia   [0371] 
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia   [0371] 
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity   [0371] 
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)   [0371] 
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas   [0371] 
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors   [0371] 
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma   [0371] 
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer   [0371] 
Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma   [0371] 
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients   [0371] 
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival   [0371] 
Immunotherapy-induced CD8(+) T Cells Instigate Immune Suppression in the Tumor   [0371] 
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells   [0371] 
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors   [0371] 
Improved survival with ipilimumab in patients with metastatic melanoma   [0371] 
Nivolumab plus ipilimumab in advanced melanoma   [0371] 
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer   [0371] 
An immune-active tumor microenvironment favors clinical response to ipilimumab   [0371] 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer   [0371] 
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma   [0371] 
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells   [0371] 
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors   [0371] 
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells   [0371] 
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma   [0371] 
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity   [0371] 
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts   [0371] 
Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden   [0371] 
An in vivo platform for tumor biomarker assessment   [0371] 
Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses   [0371] 
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2   [0371] 
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation   [0371] 
CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack   [0371] 
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains   [0371] 
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor   [0371] 
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma   [0371] 
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies   [0371] 
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin   [0371] 
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype   [0371] 
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy   [0371] 
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state   [0371] 
Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection   [0371] 
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane   [0371] 
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation   [0371] 
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 zeta Chimeric Antigen Receptor-Modified Effector CD8+ T Cells   [0371] 
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells   [0371] 
T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity   [0371] 
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor   [0371] 
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity   [0371] 
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors   [0371] 
Restoring function in exhausted CD8 T cells during chronic viral infection   [0371] 
High antigen levels are the cause of T cell exhaustion during chronic viral infection   [0371] 
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases   [0371] 
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15   [0371] 
Targeted elimination of prostate cancer by genetically directed human T lymphocytes   [0371] 
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication   [0371] 
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice   [0371] 
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation   [0371] 
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy   [0371]